EOLS 8-K 2026-11-04

Evolus, Inc. (EOLS) 8-K dated 2026-11-04 — accession 0001628280-26-070150.

Evolus, Inc. (EOLS) is a drug manufacturers - specialty & generic company listed on US.

Evolus, Inc. filed a 8-K on 2026-11-04. Accession 0001628280-26-070150.

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported EOLS revenue for 2025-12-31 was $297.2M. Net income was -$51.6M. Revenue was up 11.6% from 2024-12-31 to 2025-12-31. EOLS currently screens at market cap $597.0M.

Not investment advice. The EOLS SEC hub lists recent forms. The stock page is the research view.